Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 2/20 | 0.51 |
| ▸ | CPT1A | P50416 | 2/20 | 0.51 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | EIF4E | P06730 | 2/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2304427 | 1.00 | CPT2 (0.51) | CPT2CPT1ACPT1BUSP30UCHL1 | |
| SCHEMBL2308250 | 0.85 | GAA (0.50) | CPT2CPT1ABAZ2AMAOB | |
| SCHEMBL2308254 | 0.85 | GAA (0.50) | CPT2CPT1ABAZ2AMAOB | |
| SCHEMBL2308432 | 0.82 | HPGDS (0.49) | CPT1ACYP1A2BAZ2AMAOB | |
| SCHEMBL2308438 | 0.82 | HPGDS (0.49) | CPT1ACYP1A2BAZ2AMAOB | |
| SCHEMBL4260528 | 0.81 | HPGDS (0.58) | CPT2CPT1ACPT1BUSP30UCHL1 | |
| SCHEMBL2306322 | 0.80 | CPT1A (0.52) | CPT2CPT1ACPT1BBAZ2A | |
| SCHEMBL2306326 | 0.80 | CPT1A (0.52) | CPT2CPT1ACPT1BBAZ2A | |
| Bromide SCHEMBL2970790 | 0.80 | HPGDS (0.57) | CPT2CPT1ACPT1BUSP30UCHL1 | |
| SCHEMBL4518898 | 0.78 | HPGDS (0.50) | CPT1ACYP1A2BAZ2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039487-B2 | Piperidine-amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2155738-B1 | PIPERIDINE-AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-03 | — | — | EP | disclosed |
| EP-2155738-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMAN-LA ROCHE AG (CH) | 2008-12-04 | — | — | US | disclosed |
| WO-2008145596-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | CPT1A, CPT1B, CPT2 | CPT2 3/4885CPT1A 1/4885CPT1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.